90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years, Cancer Med, vol.5, pp.1093-1100, 2016. ,
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma, J Clin Oncol, vol.26, pp.5156-64, 2008. ,
R)) (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned?, Crit Rev Oncol Hematol, vol.105, pp.5-17, 2016. ,
Radioimmunotherapy for B-cell non-hodgkin lymphomas, Cancer Control, vol.19, pp.196-203, 2012. ,
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas, J Clin Oncol, vol.19, pp.3918-3946, 2001. ,
Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial, J Clin Oncol, vol.90, pp.308-321, 2013. ,
High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas, Br J Haematol, vol.139, pp.590-599, 2007. ,
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma, J Clin Oncol, vol.25, pp.1396-402, 2007. ,
Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy, Blood, vol.113, pp.1412-1433, 2009. ,
Fractionated (90)Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria, J Clin Oncol, vol.32, pp.212-220, 2014. ,
Novel antibody-based therapies for acute lymphoblastic leukemia, Hematology Am Soc Hematol Educ Program, pp.243-252, 2011. ,
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice, J Nucl Med, vol.43, pp.1507-1536, 2002. ,
90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study, Lancet Haematol, vol.2, pp.108-125, 2015. ,
Consolidation anti-CD22 fractionated radioimmunotherapy with (90)Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial, Lancet Haematol, vol.4, issue.16, pp.30168-30173, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01658792
An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies, Curr Pharm Des, vol.14, pp.2023-2062, 2008. ,
Murine models in mantle cell lymphoma, Best Pract Res Clin Haematol, vol.25, pp.153-63, 2012. ,
Canine lymphoma: a review, Vet Q, vol.36, pp.76-104, 2016. ,
Defining the value of a comparative approach to cancer drug development, Clin Cancer Res, vol.22, pp.2133-2141, 2016. ,
A comparative oncology study of iniparib defines its pharmacokinetic profile and biological activity in a naturally-occurring canine cancer model, PLoS ONE, vol.11, 2016. ,
Physiologically based pharmacokinetic modeling is essential in 90Y-labeled anti-CD66 radioimmunotherapy, PLoS ONE, vol.10, p.127934, 2015. ,
Populationbased modeling improves treatment planning before (90)Y-labeled anti-CD66 antibody radioimmunotherapy, Cancer Biother Radiopharm, vol.30, pp.285-90, 2015. ,
Establishment and characterization of a novel canine Bcell line derived from a spontaneously occurring diffuse large cell lymphoma, Leuk Res, vol.34, pp.932-940, 2010. ,
Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours, Vet Comp Oncol, vol.15, pp.932-51, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01414822
The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors, Proc Natl Acad Sci, vol.83, pp.9413-9420, 1986. ,
Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril, Biochem Biophys Res Commun, vol.80, pp.849-57, 1978. ,
A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies, Nucl Med Biol, vol.22, pp.387-90, 1995. ,
Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia, Am J Clin Pathol, vol.140, pp.813-821, 2013. ,
The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody, Int J Cancer, vol.71, pp.429-464, 1997. ,
The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction, J Immunol, vol.170, pp.3534-3577, 2003. ,
Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells, Cancer Res, vol.52, pp.2907-2922, 1992. ,
Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody, Int J Rad Appl Instrum B, vol.17, pp.201-208, 1990. ,
CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells, J Immunol, vol.186, pp.1554-63, 2011. ,
Constitutive endocytosis and degradation of CD22 by human B cells, J Immunol, vol.154, pp.4466-75, 1995. ,
Modulation of transferrin receptor expression and function by anti-transferrin receptor antibodies and antibody fragments, Exp Cell Res, vol.182, pp.215-248, 1989. ,
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model, PLoS ONE, vol.13, p.195802, 2018. ,
Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22, Cancer Immunol Immunother, vol.44, pp.179-88, 1997. ,
Comparative functional characterization of canine IgG subclasses, Vet Immunol Immunopathol, vol.157, pp.31-41, 2014. ,